Genetic testing in patients with metastatic castration-resistant prostate cancer primarily aims to identify targetable mutations. However, the results of genetic testing may uncover unanticipated hereditary mutations and genetic predisposition.

The latest review proposes a model to incorporate genetic testing in routine clinical practice. A brief pre-test counselling by managing clinicians followed by somatic testing can reduce current bottlenecks at genetic counselling stage, for early commencement of therapy. Early detection strategies for patients harbouring genetic mutations are critical to increase overall survival and quality of life.

^{Illustration by Xinyu Li}